Pekin Hardy Strauss Inc. Buys New Position in CRISPR Therapeutics AG $CRSP

Pekin Hardy Strauss Inc. bought a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 26,775 shares of the company’s stock, valued at approximately $1,481,000.

A number of other hedge funds have also recently modified their holdings of CRSP. Canal Insurance CO purchased a new position in CRISPR Therapeutics during the 1st quarter valued at $1,670,000. Quantinno Capital Management LP increased its stake in CRISPR Therapeutics by 613.5% in the first quarter. Quantinno Capital Management LP now owns 47,989 shares of the company’s stock worth $2,283,000 after purchasing an additional 41,263 shares during the period. KBC Group NV increased its stake in CRISPR Therapeutics by 3,999.9% in the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock worth $5,558,000 after purchasing an additional 113,997 shares during the period. Raiffeisen Bank International AG purchased a new stake in CRISPR Therapeutics in the second quarter worth $1,127,000. Finally, Shah Wealth Advisors LLC purchased a new stake in CRISPR Therapeutics in the second quarter worth $3,767,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Up 3.1%

NASDAQ:CRSP traded up $1.51 during mid-day trading on Friday, reaching $50.07. The company’s stock had a trading volume of 1,234,187 shares, compared to its average volume of 1,494,760. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics AG has a 1 year low of $44.12 and a 1 year high of $63.45. The stock has a fifty day moving average of $53.28 and a 200-day moving average of $52.81. The firm has a market capitalization of $4.84 billion, a PE ratio of -10.56 and a beta of 1.92.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, November 2nd. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09). CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 24.96%. The business had revenue of $12.67 million for the quarter, compared to analysts’ expectations of $14.75 million. CRISPR Therapeutics’s revenue for the quarter was up 1311.1% on a year-over-year basis. Equities research analysts forecast that CRISPR Therapeutics AG will post -4.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group reissued a “neutral” rating and set a $55.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Wall Street Zen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. William Blair raised shares of CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. HC Wainwright reiterated a “buy” rating on shares of CRISPR Therapeutics in a report on Friday, October 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $69.69.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Citigroup raised its price target on CRISPR Therapeutics, a potentially supportive signal for investor sentiment; the report did not provide the new target in the available details. Citigroup price target report
• Positive Sentiment: Brookline Capital Markets substantially improved its forecasts, revising projected losses to $4.74 per share for FY2026 from $5.63 and to $3.83 for FY2027 from $4.51. HC Wainwright also made smaller upward adjustments to several quarterly and annual estimates and maintains a Buy rating. Better-than-previous forecasts could support the shares, although losses remain expected. Brookline Capital Markets comments CRISPR Therapeutics analyst estimates
• Neutral Sentiment: RBC Capital assigned CRISPR Therapeutics a Hold rating, indicating a more cautious view than the Buy calls but not a direct downgrade. RBC Capital Hold rating
• Neutral Sentiment: CRSP is attracting increased attention among Zacks.com users, but the “trending stock” coverage does not itself report a new business or clinical development. Zacks trending-stock article

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 47,837 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the transaction, the chief executive officer directly owned 311,899 shares of the company’s stock, valued at $15,526,332.22. This trade represents a 13.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel James Kasinger sold 1,040 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $49.26, for a total transaction of $51,230.40. Following the completion of the transaction, the general counsel directly owned 95,857 shares of the company’s stock, valued at $4,721,915.82. This trade represents a 1.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 93,558 shares of company stock worth $4,881,663 over the last quarter. 5.20% of the stock is currently owned by company insiders.

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.